Background: Rapid drug desensitization permits continued chemotherapy, but no validated blood measurement predicts breakthrough reactions during desensitization. Objective: To compare paired plasma metabolomic and lipidomic changes during chemotherapy desensitization with those in tolerant controls, and to describe breakthrough and omalizumab encounters. Methods: In this pilot study, 10 patients undergoing carboplatin or paclitaxel desensitization and four tolerant controls receiving standard infusions contributed 76 draws across 39 encounters (37 with paired pre- and post-infusion draws).
Plasma Metabolomics During Chemotherapy Desensitization: A Pilot Study
calendar_today
October 30, 2026
person
Asiaee, A., Sherrod, S. D., Codreanu, S. G., Leaptrot, K. L., Schrimpe-Rutledge, A. C., McLean, J. A., McGinnis, M. A., Petrie, H. C., Prescott, L. S., Brown, A. J., Alvarez, R., Phillips, E. J., Stone, C. A.
domain
medrxiv